Globus, Nevro

Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year over year. Globus anticipates $2.80 billion to $2.90 billion in sales after the closing of the purchase, with non-GAAP earnings per share ranging from $3.10 to $3.40.
Globus Medical To Acquire Nevro For $250 Mln
Globus Medical (GMED), a musculoskeletal solutions company, Thursday agreed to acquire Nevro Corp. (NVRO), a medical device company,
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,
Globus Medical to acquire Nevro for $5.85 per share
EST Globus Medical (GMED) to acquire Nevro (NVRO) for $5.85 per share Published first on TheFly – the ultimate source for real-time,
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical to acquire spine company for $250M
Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about $250 million. The deal is slated to close in the second quarter.
medtechdive10m
Globus to buy Nevro for $250M
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Globus acquisition of Nevro complicates story, says Stifel
Stifel Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) an “unexpected move.” The firm says that while it wants to be ...
TMCnet5h
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Nasdaq14d
Here's Why you Should Add Nevro Stock to Your Portfolio Now
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...